Soleno Therapeutics (SLNO) Expected to Announce Earnings on Wednesday

Soleno Therapeutics (NASDAQ:SLNO) will likely be releasing its Q4 2025 results after the market closes on Wednesday, February 25th. Analysts expect Soleno Therapeutics to post earnings of $0.59 per share and revenue of $88.5470 million for the quarter. Individuals may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Wednesday, February 25, 2026 at 4:30 PM ET.

Soleno Therapeutics Trading Up 3.4%

Shares of Soleno Therapeutics stock opened at $38.50 on Wednesday. Soleno Therapeutics has a 1 year low of $36.67 and a 1 year high of $90.32. The company has a debt-to-equity ratio of 0.10, a current ratio of 16.08 and a quick ratio of 15.88. The business has a 50 day moving average price of $44.27 and a 200 day moving average price of $55.55. The company has a market capitalization of $2.07 billion, a P/E ratio of -20.92 and a beta of -3.16.

Institutional Investors Weigh In On Soleno Therapeutics

A number of institutional investors have recently bought and sold shares of SLNO. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Soleno Therapeutics by 1.1% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,360 shares of the company’s stock worth $1,242,000 after purchasing an additional 189 shares during the period. Raymond James Financial Inc. purchased a new stake in shares of Soleno Therapeutics during the 2nd quarter valued at $25,000. Danske Bank A S acquired a new stake in shares of Soleno Therapeutics during the 3rd quarter worth $27,000. Osaic Holdings Inc. raised its position in shares of Soleno Therapeutics by 97.7% in the 2nd quarter. Osaic Holdings Inc. now owns 856 shares of the company’s stock worth $72,000 after buying an additional 423 shares during the period. Finally, Global Retirement Partners LLC raised its position in shares of Soleno Therapeutics by 519.0% in the 4th quarter. Global Retirement Partners LLC now owns 619 shares of the company’s stock worth $29,000 after buying an additional 519 shares during the period. 97.42% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

SLNO has been the topic of several recent research reports. Wall Street Zen upgraded Soleno Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. Wolfe Research set a $60.00 target price on shares of Soleno Therapeutics in a report on Monday, January 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Soleno Therapeutics in a report on Thursday, January 22nd. Zacks Research lowered shares of Soleno Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, February 3rd. Finally, Robert W. Baird set a $107.00 target price on shares of Soleno Therapeutics in a research report on Tuesday, January 13th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $110.62.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.